-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Uc0JaA6mjhQRSYC+duB29QYQ8XFRTfvxexZfaJPsBYw2gdPy8uFtHRXRYavyBwOB /NAJRzIkvXS0c0shVKDVsA== 0001047469-98-006040.txt : 19980218 0001047469-98-006040.hdr.sgml : 19980218 ACCESSION NUMBER: 0001047469-98-006040 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19980213 SROS: NASD SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001012140 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943154463 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-45955 FILM NUMBER: 98538590 BUSINESS ADDRESS: STREET 1: 3031 RESEARCH DR STREET 2: BLDG A CITY: RICHMOND STATE: CA ZIP: 94806 BUSINESS PHONE: 5102229700 MAIL ADDRESS: STREET 1: 3031 RESEARCH DRIVE STREET 2: 3031 RESEARCH DRIVE CITY: RICHMOND STATE: CA ZIP: 94806 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CHIRON CORP CENTRAL INDEX KEY: 0000706539 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 942754624 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 4560 HORTON ST CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 5106558730 SC 13G/A 1 SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Onyx Pharmaceuticals, Inc. - ------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $0.001 Par Value - ------------------------------------------------------------------------------- (Title of Class of Securities) Common Stock: 683399-10-9 - ------------------------------------------------------------------------------- (CUSIP Number) *THE REMAINDER OF THIS COVER PAGE SHALL BE FILLED OUT FOR A REPORTING PERSON'S INITIAL FILING ON THIS FORM WITH RESPECT TO THE SUBJECT CLASS OF SECURITIES, AND FOR ANY SUBSEQUENT AMENDMENT CONTAINING INFORMATION WHICH WOULD ALTER DISCLOSURES PROVIDED IN A PRIOR COVER PAGE. THE INFORMATION REQUIRED IN THE REMAINDER OF THIS COVER PAGE SHALL NOT BE DEEMED TO BE "FILED" FOR THE PURPOSE OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934 ("ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION OF THE ACT BUT SHALL BE SUBJECT TO ALL OTHER PROVISIONS OF THE ACT (HOWEVER, SEE THE NOTES). CUSIP NO. 683399-10-9 13G Page 2 of 5 --------------------- ----------- - ------------------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Chiron Corporation, I.R.S. Identification No. 94-2754624 - ------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / - ------------------------------------------------------------------------------- 3. SEC USE ONLY - ------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - ------------------------------------------------------------------------------- 5. SOLE VOTING POWER 919,030 shares of Common Stock ------------------------------------------------------------ NUMBER OF 6. SHARED VOTING POWER SHARES BENEFICIALLY OWNED BY EACH -0- REPORTING ------------------------------------------------------------ PERSON WITH 7. SOLE DISPOSITIVE POWER 919,030 shares of Common Stock ------------------------------------------------------------ 8. SHARED DISPOSITIVE POWER -0- - ------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 919,030 shares of Common Stock - ------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* - ------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 Common Stock: 8.16% - ------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! PAGE 2 OF 5 PAGES CUSIP NO. 683399-10-9 13G Page 3 of 5 --------------------- ----------- ITEM 1(a). NAME OF ISSUER: Onyx Pharmaceuticals, Inc. - ------------------------------------------------------------------------------- ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 3031 Research Drive, Richmond, CA 94806 - ------------------------------------------------------------------------------- ITEM 2(a). NAME OF PERSON FILING: Chiron Corporation - ------------------------------------------------------------------------------- ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: 4560 Horton Street, Emeryville, CA 94608 - ------------------------------------------------------------------------------- ITEM 2(c). CITIZENSHIP: Delaware - ------------------------------------------------------------------------------- ITEM 2(d). TITLE OF CLASS OF SECURITIES: Common Stock, $0.001 Par Value - ------------------------------------------------------------------------------- ITEM 2(e). CUSIP NUMBER: Common Stock: 683399-10-9 - ------------------------------------------------------------------------------- ITEM 3. Not applicable - ------------------------------------------------------------------------------- PAGE 3 OF 5 PAGES CUSIP NO. 683399-10-9 13G Page 4 of 5 --------------------- ----------- ITEM 4. OWNERSHIP. If the percent of the class owned as of December 31 of the year covered by the statement, or as of the last day of any month described in Rule 13d-1 (b) (2), if applicable, exceeds five percent, provide the following information as of that date and identify those shares which there is a right to acquire. (a) Amount Beneficially Owned: Common Stock: 919,030 shares (b) Percent of Class: Common Stock: 8.16% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 919,030 shares of Common Stock (ii) shared power to vote or to direct the vote: None (iii) sole power to dispose or to direct the disposition of: 919,030 shares of Common Stock (iv) shared power to dispose or to direct the disposition of: None - ------------------------------------------------------------------------------- ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. Not applicable - ------------------------------------------------------------------------------- PAGE 4 OF 5 PAGES CUSIP NO. 683399-10-9 13G Page 5 of 5 --------------------- ----------- ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. Not applicable - ------------------------------------------------------------------------------- ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. Not applicable - ------------------------------------------------------------------------------- ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. Not applicable - ------------------------------------------------------------------------------- ITEM 9. NOTICE OF DISSOLUTION OF GROUP. Not applicable - ------------------------------------------------------------------------------- ITEM 10. CERTIFICATION. Not applicable - ------------------------------------------------------------------------------- SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. CHIRON CORPORATION Date: February 12, 1998 By: /s/WILLIAM G. GREEN ----------------------------------------------- Signature William G. Green, Senior Vice President, Secretary and General Counsel -------------------------------------------------- Name/Title PAGE 5 OF 5 PAGES -----END PRIVACY-ENHANCED MESSAGE-----